特发性肥大细胞活化综合征与放射治疗:一例病例研究、文献复习及肥大细胞疾病与放疗讨论
本文报告一例62岁女性特发性肥大细胞活化综合征(MCAS)患者接受左侧乳腺浸润性小叶癌保乳术后放疗的病例:全乳外照射4500 cGy后瘤床加量1000 cGy,仅出现1级放射性皮炎;两年后腰椎病灶接受单次2400 cGy立体定向体部放疗,放疗期间未出现照射野内皮肤或全身性MCAS症状 flare。文献复习指出,目前尚无MCAS或其他特发性肥大细胞疾病患者接受放疗的报道,此类疾病不应视为外照射放疗的禁忌证。
要点
- MCAS患者接受全乳放疗4500 cGy加瘤床加量1000 cGy仅出现1级放射性皮炎。
- 腰椎单次2400 cGy立体定向放疗期间未出现照射野内皮肤或全身性MCAS症状 flare。
- 特发性肥大细胞疾病不应视为外照射放疗的禁忌证。
核心结论
- 特发性肥大细胞疾病如MCAS及原发性肥大细胞疾病不应被视为外照射放疗的禁忌证。
- 该患者人群似乎可耐受放疗而不出现全身性症状 flare。
研究设计与样本
- 单例病例报告结合文献复习:一例62岁女性MCAS患者因左侧乳腺浸润性小叶癌(AJCC第7版IIB期,pT3 pN0 M0)接受保乳术后放疗。
主要发现
- 全乳外照射4500 cGy后瘤床加量1000 cGy,出现1级放射性皮炎。
- 两年后腰椎病灶接受单次2400 cGy立体定向体部放疗,放疗期间未出现照射野内皮肤或全身性MCAS症状 flare。
- 文献中尚无MCAS或其他特发性肥大细胞疾病患者接受放疗的报道。
关键数值与推荐
- 全乳外照射剂量4500 cGy,瘤床加量1000 cGy,出现1级放射性皮炎。
- 腰椎立体定向体部放疗单次2400 cGy,未出现照射野内皮肤或全身性MCAS症状 flare。
临床怎么用
- 对MCAS或其他特发性肥大细胞疾病患者,不应将外照射放疗视为禁忌。
- 放疗期间需关注皮肤反应及MCAS症状 flare,但该病例提示耐受性良好。
局限性
- 仅为单例病例报告,文献中缺乏同类患者接受放疗的报道,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mast Cell Activation Syndrome (MCAS) is classified as an idiopathic mast cell disorder where inconsistent or unknown triggers release inflammatory mediators and cause a constellation of symptoms. Studies demonstrate mast cells increase histamine, tryptase, and inflammatory cytokine expression following ionizing radiation. Additionally, there are cases of cutaneous mastocytosis developing within the initial radiation field suggesting mast cells play a role in local tissue reactions. Literature is sparse on radiation induced toxicity in patients with mast cell disorders. CASE PRESENTATION: A 62 year old female patient with a history of MCAS received breast conservation therapy for invasive lobular carcinoma of the left breast initially AJCC 7th Stage IIB, pT3 pN0 M0. The patient underwent external beam radiotherapy (EBRT) and received 4500 cGy to the left whole breast, followed by a 1000 cGy boost to the lumpectomy cavity. She developed grade 1 radiation dermatitis. Two years later she progressed distantly and received stereotactic body radiation therapy to a lumbar vertebrae lesion to a dose of 2400 cGy in a single fraction. She developed no in-field dermatologic or systemic flare in her MCAS symptoms during radiation therapy. CONCLUSIONS: To our knowledge there are no reported cases in the literature of patients diagnosed with MCAS or other idiopathic mast cell disorders undergoing radiation therapy. Idiopathic mast cell disorders such as MCAS and primary mast cell disorders alike should not be considered a contraindication to treatment with EBRT. This patient population appears to tolerate treatment without systemic flares in symptoms.
引用
- Landy RE, Stross WC, May JM, et al. Idiopathic mast cell activation syndrome and radiation therapy: a case study, literature review, and discussion of mast cell disorders and radiotherapy. Radiat Oncol. 2019. PMID: 31818306. doi:10.1186/s13014-019-1434-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。